iSpecimen Inc.
iSpecimen Inc. operates a biospecimen procurement marketplace that connects medical researchers with hospitals, laboratories, and other specimen supply sites. The company uses proprietary software to search, manage workflow, and administer the sourcing and delivery of human biospecimens and associated data across its network.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSourcing and delivering human specimens from hospitals, laboratories, and other supply sites.
Proprietary tools for search, order routing, and coordination between researchers and suppliers.
Compliance, user management, reporting, and specimen-related data handling.
Products
Reported · share of revenue- Products89.9 %
- Shipping and Handling10.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
iSpecimen sells primarily to medical research customers that need specific biospecimens and associated data for studies, trials, and discovery work. It also serves hospitals, laboratories, and other supply sites that participate as specimen sources within the marketplace network. The platform is designed to reduce the friction of finding, qualifying, and moving specimens between these two sides of the market.
Buy biospecimens and associated data for research, assay development, and study execution.
Provide specimens into the marketplace and participate because the platform helps monetize available samples.
Use the marketplace to source hard-to-find specimens for translational and clinical research.
Contribute specimens and related data when they can meet specific collection and data requirements.
Strategy
iSpecimen’s strategy is to grow usage on both sides of its marketplace by retaining researchers and expanding supplier participation. The company also invests in search, workflow, data, and administration features to improve platform engagement and liquidity, which are central to matching supply with demand efficiently. Management also indicates interest in adjacent opportunities that can leverage the marketplace infrastructure.
A deeper two-sided network improves specimen matching and makes the platform more useful to both buyers and suppliers.
Better search, workflow, and reporting tools can improve user engagement and operational efficiency.
The marketplace infrastructure may support related services beyond core biospecimen procurement.
Geography
The company is based in the United States and its disclosures emphasize a networked marketplace rather than a single manufacturing footprint. Its operations depend on the location of participating hospitals, laboratories, and research customers, so geography is driven by where specimens can be sourced and where research demand exists. The available excerpts do not provide a formal country revenue split.
Risks
The business depends on continued participation from both specimen suppliers and research customers, so weak network liquidity can reduce match rates and revenue opportunities. It is also exposed to life science research spending cycles, specimen availability, compliance requirements, and the operational complexity of sourcing perishable or highly specified materials on a just-in-time basis. As a smaller public company, it also faces financing, dilution, and execution risk while it develops its platform.
The platform only works well if researchers and suppliers are both active, so weak participation on either side can impair matching and revenue generation.
Exposure: Core business model
The company must locate, qualify, and deliver specific specimens quickly, and failures can affect customer satisfaction and repeat business.
Exposure: Just-in-time procurement model
As a smaller company, access to capital can influence platform investment and operating flexibility.
Exposure: Corporate funding
Customer demand depends on research budgets and project activity, which can fluctuate with broader funding conditions.
Exposure: Medical research customers
The marketplace handles user, specimen, and compliance information, so process failures could create legal or reputational issues.
Exposure: Platform administration
Accounting
Judgemental itemsRevenue is generated when specimens are procured and delivered, so fulfillment timing affects reported period results.
Impact: Specimen orders and delivery completion
The company states that critical accounting policies rely on estimates that can change with actual outcomes.
Impact: Assets, liabilities, revenues, and expenses
A just-in-time procurement model can create variability in revenue and margins based on order timing and specimen mix.
Impact: Period-to-period operating results
Debt or equity financing can affect interest expense, dilution, and balance sheet presentation.
Impact: Capital structure and earnings per share
Similar listed companies
Publicly listed companies with a comparable business focus.
iBio, Inc.
IBIO · Pharmaceutical Preparations
International Stem Cell CORP
ISCO · Pharmaceutical Preparations
Repligen Corporation
RGEN · Biological Products, (No Diagnostic Substances)
Standard BioTools Inc
LAB · Pharmaceutical Preparations
IB Acquisition Corp.
IBACR · Services-Commercial Physical & Biological Research
Celularity Inc
CELU · Pharmaceutical Preparations
Last updated: 24/09/2026